SG11201806625WA - Non-invasive ocular drug delivery insert technology - Google Patents

Non-invasive ocular drug delivery insert technology

Info

Publication number
SG11201806625WA
SG11201806625WA SG11201806625WA SG11201806625WA SG11201806625WA SG 11201806625W A SG11201806625W A SG 11201806625WA SG 11201806625W A SG11201806625W A SG 11201806625WA SG 11201806625W A SG11201806625W A SG 11201806625WA SG 11201806625W A SG11201806625W A SG 11201806625WA
Authority
SG
Singapore
Prior art keywords
drug
insert
international
coimbra
ocular
Prior art date
Application number
SG11201806625WA
Inventor
Leite Machado Mariz Marcos João Mota
Ferreira Calvinho Paula Cristina Nunes
Gil Maria Helena Mendes
Murta Joaquim Carlos Neto
Original Assignee
Univ De Coimbra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ De Coimbra filed Critical Univ De Coimbra
Publication of SG11201806625WA publication Critical patent/SG11201806625WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29DPRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00Producing optical elements, e.g. lenses or prisms
    • B29D11/02Artificial eyes from organic plastic material
    • B29D11/023Implants for natural eyes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29DPRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00Producing optical elements, e.g. lenses or prisms
    • B29D11/00009Production of simple or compound lenses
    • B29D11/00038Production of contact lenses
    • B29D11/00096Production of contact lenses for delivering compositions, e.g. drugs to the eye
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2067/00Use of polyesters or derivatives thereof, as moulding material
    • B29K2067/04Polyesters derived from hydroxycarboxylic acids
    • B29K2067/046PLA, i.e. polylactic acid or polylactide
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035Medical or pharmaceutical agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0085Copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/137934 Al 17 August 2017 (17.08.2017) WIPO I PCT 11111111111111011101111111111101011111011101110111111111111101111111111111111110111111 (51) International Patent Classification: A61K 9/00 (2006.01) 961% 31/192 (2006.01) A61K 47/34 (2017.01) A61K 31/4709 (2006.01) (21) International Application Number: PCT/IB2017/050731 (22) International Filing Date: 10 February 2017 (10.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 109154 12 February 2016 (12.02.2016) PT (71) Applicant: UNIVERSIDADE DE COIMBRA [PT/PT]; Paco das Escolas, 3004-351 Coimbra (PT). (72) Inventors: MOTA LEITE MACHADO MARIZ, Mar- cos Joao; Rua Antonio Goncalves, if 95 R/C A Qta da Varzea, Santa Clara, 3040-241 Coimbra (PT). NUNES FERREIRA CALVINHO, Paula Cristina; Urbanizacao Nova Conimbriga, n° 16, Condeixa-a-Velha, 3150-230 Condeixa-a-Nova (PT). MENDES GIL, Maria Helena; Rua Dias da Silva, n° 108 R/C Dto, 3000-135 Coimbra (PT). NETO MURTA, Joaquim Carlos; Rua Dias da Silva, n° 88, 3000-135 Coimbra (PT). (74) Agent: PEREIRA DA CRUZ, Joao; J. Pereira Da Cruz, S.a., Rua Vitor Cordon, 14, 1249-103 Lisboa (PT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 17 / 137 93 4 Al (54) Title: NON-INVASIVE OCULAR DRUG DELIVERY INSERT TECHNOLOGY (57) : Non-invasive Ocular Drug Delivery Insert Technology The invention concerns an ocular insert which is a new biocompatible polymer-based controlled drug delivery system (CDDS) applicable to a variety of drugs and other compounds for the treatment of different ocular pathologies. This ocular insert allows releasing of at least one drug under suitable concentration levels during suitable periods of time. The device may be inserted in the lower or upper fornix conjunctiva, in a non-invasive way, meaning that the patient will be able to place the device himself, without intervention of medical specialized staff. The insert of the invention will release the drug in such a controlled rate that will allow the drug release up to 300 days by either a \"Fickian\" or a linear profile according to the intend purpose or pathology. The insert can be prepared with different shapes (spherical or spherical dome) and/or architectures (monolithic/layered either with or without a drug core) allowing the incorporation of at least one drug which can be re- leased at different rates. The size, shape and design of the insert is adjusted in order to tune the drug(s) delivery profile(s) and to in- hibit the risk of displacement or expulsion.
SG11201806625WA 2016-02-12 2017-02-10 Non-invasive ocular drug delivery insert technology SG11201806625WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT109154A PT109154B (en) 2016-02-12 2016-02-12 NON-INVASIVE EYE INSERT TECHNOLOGY FOR CONTROLLED DRUG RELEASE
PCT/IB2017/050731 WO2017137934A1 (en) 2016-02-12 2017-02-10 Non-invasive ocular drug delivery insert technology

Publications (1)

Publication Number Publication Date
SG11201806625WA true SG11201806625WA (en) 2018-09-27

Family

ID=58428316

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806625WA SG11201806625WA (en) 2016-02-12 2017-02-10 Non-invasive ocular drug delivery insert technology

Country Status (10)

Country Link
US (1) US11642311B2 (en)
EP (1) EP3413872A1 (en)
JP (1) JP2019504855A (en)
AU (1) AU2017217358B2 (en)
BR (1) BR112018016301A2 (en)
CA (1) CA3013878C (en)
PT (1) PT109154B (en)
RU (1) RU2749426C2 (en)
SG (1) SG11201806625WA (en)
WO (1) WO2017137934A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021524840A (en) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー Implantable device for sustained release of macromolecular drug compounds
WO2019226516A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3990042A4 (en) 2019-06-27 2023-07-19 Layerbio, Inc. Ocular device delivery methods and systems
CA3153384C (en) 2019-09-18 2024-02-13 Alcon Inc. Wet-packed soft hydrogel ocular inserts
CN113057794B (en) * 2019-12-31 2023-03-10 财团法人工业技术研究院 Ophthalmic drug delivery device and method of making same
IL301227A (en) * 2020-09-14 2023-05-01 Eyepoint Pharmaceuticals Inc Bioerodible ocular drug delivery insert and therapeutic method
CN112618480B (en) * 2020-11-10 2022-07-12 南昌大学 Preparation method of eye drug delivery system
JP2023552599A (en) * 2020-12-11 2023-12-18 エフ. ホフマン-ラ ロシュ アーゲー New polymers and their uses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US4438123A (en) 1980-03-04 1984-03-20 Merck & Co., Inc. Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US5137728A (en) * 1988-03-01 1992-08-11 Bausch & Lomb Incorporated Ophthalmic article
RU2014813C1 (en) * 1992-07-03 1994-06-30 Фирма "Токем" Method for manufacture of versatile insert used for curing corrosive burns of eyes
RU2100020C1 (en) * 1993-06-23 1997-12-27 Лейрас Ой Agent for local treatment of ophthalmic hypertension and glaucoma and a method of its preparing
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6217896B1 (en) * 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
FR2795326B1 (en) * 1999-06-28 2001-08-31 Adir SOLID THERMOFORMABLE PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
EP1347748A2 (en) * 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
WO2004058289A1 (en) 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7320690B2 (en) * 2004-05-13 2008-01-22 Biocoat Incorporated IOL insertion device with lubricious coating
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
JP5081413B2 (en) * 2005-07-29 2012-11-28 参天製薬株式会社 Non-invasive drug delivery system for posterior ocular tissue using solid composition
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US8586556B2 (en) 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
TR200708925A1 (en) * 2007-12-26 2009-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Combinations of flurbiprofen and muscle relaxants for controlled release
KR102126007B1 (en) * 2010-01-22 2020-06-24 알러간, 인코포레이티드 Intracameral sustained release therapeutic agent implants
SG10201501964QA (en) * 2010-03-16 2015-05-28 Titan Pharmaceuticals Inc Heterogeneous Implantable Devices For Drug Delivery
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
WO2012112636A1 (en) * 2011-02-18 2012-08-23 Valeant International (Barbados) Srl Cylindrical ocular inserts

Also Published As

Publication number Publication date
US20190046434A1 (en) 2019-02-14
CA3013878A1 (en) 2017-08-17
JP2019504855A (en) 2019-02-21
RU2018128943A3 (en) 2020-06-01
PT109154B (en) 2019-11-05
CA3013878C (en) 2024-06-25
AU2017217358B2 (en) 2022-09-29
BR112018016301A2 (en) 2018-12-26
EP3413872A1 (en) 2018-12-19
RU2018128943A (en) 2020-03-12
PT109154A (en) 2017-08-14
RU2749426C2 (en) 2021-06-10
AU2017217358A1 (en) 2018-08-30
WO2017137934A1 (en) 2017-08-17
US11642311B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
SG11201806625WA (en) Non-invasive ocular drug delivery insert technology
SG11201903946SA (en) Devices and methods for slurry generation
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201808135SA (en) Delivery system for prosthetic heart valve
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201900596XA (en) Cannabis composition
SG11201907034PA (en) Methods of treating influenza
SG11201806340YA (en) Zika virus vaccine
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201808214TA (en) Pyrazolopyrimidine derivatives
SG11201804778RA (en) Method of operating an injection system
SG11201910191RA (en) A peptide capable of forming a gel for use in tissue engineering and bioprinting
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201408092UA (en) Endoprosthesis and delivery device for implanting such endoprosthesis
SG11201407961WA (en) Risperidone or paliperidone implant formulation
SG11201808539WA (en) Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201901351UA (en) A patient interface, system and method
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201901137UA (en) Silk-derived protein for treating inflammation
SG11201804889XA (en) Fluid interface device for delivering fluid to and/or withdrawing fluid from a patient